

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

Hs 766T

RRID:CVCL_0334

Type: Cell Line

Proper Citation

RRID:CVCL_0334

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0334

Proper Citation: RRID:CVCL_0334

Description: Cell line Hs 766T is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic adenocarcinoma

Defining Citation: [PMID:176412](#), [PMID:283258](#), [PMID:761205](#), [PMID:1630814](#), [PMID:6500159](#), [PMID:8026879](#), [PMID:10027410](#), [PMID:10408907](#), [PMID:11169959](#), [PMID:14695172](#), [PMID:15126341](#), [PMID:15367885](#), [PMID:15688027](#), [PMID:16912165](#), [PMID:18380791](#), [PMID:19305140](#), [PMID:20418756](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Caution: TP53 mutation indicated incorrectly as being at c.542G>A in PubMed=1630814., Caution: Incorrectly reported to have no KRAS mutation in PubMed=8026879 and PubMed=15367885., Caution: Indicated as originating from a 46 year old male patient in ATCC and from a 64 year old male patient in PubMed=283258 and PubMed=761205., Population: Caucasian., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Hs 766T

Synonyms: Hs 766.T, HS-766T, Hs-766T, HS 766T, HS-766-T, Hs-766-T, HS766T, Hs766T, H766T, 766T, Hs 766

Cross References: BTO:BTO_0003267, CLO:CLO_0004102, EFO:EFO_0006590, MCCL:MCC:0000230, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-134, BioGRID_ORCS_Cell_line:417, BioSample:SAMN03471934, BioSample:SAMN03472713, BioSample:SAMN10988214, cancercellines:CVCL_0334, CCRID:1101HUM-PUMC000377, Cell_Model_Passport:SIDM00664, CGH-DB:166-1, CGH-DB:9276-4, ChEMBL-Cells:ChEMBL3308000, ChEMBL-Targets:ChEMBL612597, Cosmic:868240, Cosmic:873005, Cosmic:913311, Cosmic:922254, Cosmic:923169, Cosmic:932519, Cosmic:947401, Cosmic:948380, Cosmic:948738, Cosmic:949323, Cosmic:1006370, Cosmic:1108344, Cosmic:1122344, Cosmic:1299301, Cosmic:1320468, Cosmic:1366279, Cosmic:1518235, Cosmic:1571778, Cosmic:2434086, Cosmic:2755952, Cosmic-CLP:1298141, DepMap:ACH-000178, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1298141, GEO:GSM206513, GEO:GSM621912, GEO:GSM784692, GEO:GSM887117, GEO:GSM888188, GEO:GSM1024403, GEO:GSM1374553, GEO:GSM1374554, GEO:GSM1374555, GEO:GSM1669899, IARC_TP53:315, IARC_TP53:21071, LiGeA:CCLE_905, LINCS_LDP:LCL-1737, PharmacDB:Hs766T_596_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_0334, PubChem_Cell_line:CVCL_0334, SKY/M-FISH/CGH:1994, Wikidata:Q54896006

ID: CVCL_0334

Record Creation Time: 20220427T220610+0000

Record Last Update: 20260815T234240+0000

Ratings and Alerts

No rating or validation information has been found for Hs 766T.

No alerts have been found for Hs 766T.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Garczyk M, et al. (2026) Targeting PI3K γ suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Cell reports, 45(4), 117188.

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. Nature

communications, 16(1), 9996.

Tang J, et al. (2025) CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer. *Cancer letters*, 622, 217713.

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. *Cell*.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. *Cell reports. Medicine*, 5(5), 101523.

Shrestha H, et al. (2024) The Janus kinase 1 is critical for pancreatic cancer initiation and progression. *Cell reports*, 43(5), 114202.

Hartl L, et al. (2024) Hypoxia Abrogates Tumor-Suppressive Activities of C/EBP β in Pancreatic Cancer. *International journal of molecular sciences*, 25(17).

Paul MC, et al. (2023) Non-canonical functions of SNAIL drive context-specific cancer progression. *Nature communications*, 14(1), 1201.

Wei D, et al. (2023) Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression. *Digestive diseases and sciences*.

Vallés-Martí A, et al. (2023) Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. *Cell reports*, 42(6), 112581.

Abt ER, et al. (2022) Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. *Cell reports*, 38(2), 110236.

Martínez-Bosch N, et al. (2022) Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. *EBioMedicine*, 75, 103797.

Huynh MV, et al. (2022) Functional and biological heterogeneity of KRASQ61 mutations. *Science signaling*, 15(746), eabn2694.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.

Duan Y, et al. (2021) Protein modifications throughout the lung cancer proteome unravel the cancer-specific regulation of glycolysis. *Cell reports*, 37(12), 110137.

Arias-Pinilla GA, et al. (2020) Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin $\alpha 3$ in human pancreatic cancer. *Scientific reports*, 10(1), 537.

Salvador-Barbero B, et al. (2020) CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. *Cancer cell*, 37(3), 340.